-
公开(公告)号:US09963429B2
公开(公告)日:2018-05-08
申请号:US14911352
申请日:2014-09-01
Applicant: IDEMITSU KOSAN CO., LTD.
Inventor: Yumiko Mizuki , Hirokatsu Ito , Tasuku Haketa , Tomoharu Hayama , Kazuki Nishimura , Masahiro Kawamura , Mitsuru Shibata
IPC: H01L51/00 , C07D209/88 , C07D209/86 , C09K11/02 , C09K11/06 , C07D403/14 , H01L51/50
CPC classification number: C07D209/86 , C07D209/88 , C07D403/14 , C09K11/025 , C09K11/06 , C09K2211/1007 , C09K2211/1029 , C09K2211/185 , H01L51/0054 , H01L51/0059 , H01L51/0067 , H01L51/0072 , H01L51/0085 , H01L51/5012 , H01L51/5016 , H01L51/5056 , H01L51/5064
Abstract: A novel carbazole derivative represented by formula (1) in which two or more groups each having a specific structure, such as a carbazolyl group, are bonded to two or more of 2-, 3- and 4-positions of the carbazole derivative is useful as a material for organic electroluminescence devices. A material for organic electroluminescence devices including the carbazole derivative, an organic electroluminescence device employing the carbazole derivative, and an electronic equipment are described. wherein at least two selected from B1 to B3 are represented by formula (2) and A, X1 to X4, L, n, Y, and R1 to R8 are as defined in claim 1.
-
公开(公告)号:US20180079758A1
公开(公告)日:2018-03-22
申请号:US15809437
申请日:2017-11-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Douglas G. Batt , Myra Beaudoin Bertrand , George V. Delucca , Michael A. Galella , Soo Sung Ko , Charles M. Langevine , Qingjie Liu , Qing Shi , Anurag S. Srivastava , Joseph A. Tino , Scott Hunter Watterson
IPC: C07D513/04 , C07D471/04 , C07D403/10 , C07D209/88 , C07D239/70
CPC classification number: C07D513/04 , C07B2200/07 , C07B2200/13 , C07D209/88 , C07D239/70 , C07D403/10 , C07D471/04
Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
公开(公告)号:US20180057444A1
公开(公告)日:2018-03-01
申请号:US15659320
申请日:2017-07-25
Applicant: WILLIAM MARSH RICE UNIVERSITY
Inventor: HONGYIN GAO , Zhe ZHOU , Laszlo KURTI
IPC: C07C209/66 , C07C37/01 , C07D295/135 , C07D307/79 , C07D317/66 , C07D317/46 , C07C319/20 , C07D317/28 , C07D309/12 , C07D213/73 , C07D213/04 , C07D209/04 , C07D277/82 , C07D333/20 , C07D307/91 , C07D209/88 , C07J41/00 , C07D333/16 , C07C41/26 , C07D317/64 , C07D295/096 , C07D317/20 , C07B43/04 , C07B41/02
CPC classification number: C07C209/66 , C07B41/02 , C07B43/04 , C07C37/01 , C07C37/055 , C07C37/64 , C07C41/26 , C07C213/02 , C07C227/06 , C07C303/30 , C07C319/20 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2603/18 , C07C2603/26 , C07D209/04 , C07D209/88 , C07D213/04 , C07D213/73 , C07D215/38 , C07D277/82 , C07D295/096 , C07D295/135 , C07D307/79 , C07D307/91 , C07D309/12 , C07D311/58 , C07D317/20 , C07D317/28 , C07D317/46 , C07D317/64 , C07D317/66 , C07D333/16 , C07D333/20 , C07D333/36 , C07J41/0011 , C07C211/58 , C07C217/94 , C07C211/59 , C07C211/61 , C07C211/47 , C07C211/44 , C07C217/80 , C07C211/51 , C07C323/36 , C07C309/30 , C07C229/56 , C07C229/60 , C07C219/34 , C07C39/235 , C07C39/14 , C07C39/15 , C07C39/12 , C07C39/20 , C07C39/205 , C07C43/23
Abstract: In one aspect, the present disclosure provides methods of preparing a primary or secondary amine and hydroxylated aromatic compounds. In some embodiments, the aromatic compound may be unsubstituted, substituted, or contain one or more heteroatoms within the rings of the aromatic compound. The methods described herein may be carried out without the need for transition metal catalysts or harsh reaction conditions.
-
公开(公告)号:US20170373265A1
公开(公告)日:2017-12-28
申请号:US15606350
申请日:2017-05-26
Inventor: Yeonhwa LEE , Sangsoo KIM , Duckjung LEE , Joongu LEE , Sehoon JEONG , Jiyoung CHOUNG
IPC: H01L51/50 , C07C211/61 , C07D209/86 , C07D209/88 , C07D307/91 , C07D405/12 , C07D409/12 , C09K11/06 , H01L51/56 , C07C211/54 , H01L51/00 , C07D401/12 , C07C2603/97 , C07C2603/18
CPC classification number: H01L51/5072 , C07C211/54 , C07C211/61 , C07C2603/18 , C07C2603/97 , C07D209/86 , C07D209/88 , C07D307/91 , C07D401/12 , C07D405/12 , C07D409/12 , C09K11/06 , C09K2211/1029 , C09K2211/185 , H01L51/0052 , H01L51/0056 , H01L51/0058 , H01L51/006 , H01L51/0061 , H01L51/0067 , H01L51/0072 , H01L51/0073 , H01L51/0074 , H01L51/0085 , H01L51/5004 , H01L51/5012 , H01L51/5016 , H01L51/504 , H01L51/506 , H01L51/5092 , H01L51/5221 , H01L51/56 , H01L2251/301 , H01L2251/303 , H01L2251/552 , H01L2251/558
Abstract: An organic light-emitting device includes a first electrode, a second electrode facing the first electrode, and an organic layer disposed between the first electrode and the second electrode, the organic layer including an emission layer, a hole transport region between the first electrode and the emission layer, and an electron transport region between the emission layer and the second electrode, wherein the electron transport region includes a first layer that includes a metal oxide and a metal halide, and wherein the first layer is not in direct contact with the emission layer.
-
公开(公告)号:US20170365796A1
公开(公告)日:2017-12-21
申请号:US15597771
申请日:2017-05-17
Applicant: SAMSUNG ELECTRONICS CO., LTD. , Samsung SDI Co., Ltd.
Inventor: Sangmo KIM , Dalho HUH , Jhunmo SON , Miyoung CHAE , Eunsuk KWON , Hyunjung KIM , Saeyoun LEE , Soonok JEON , Yeonsook CHUNG , Yongsik JUNG , Youngmok SON , Namheon LEE
IPC: H01L51/00 , C07D401/10 , C07D403/10 , C07D471/04 , C07D495/04 , C09K11/06 , C07D209/86 , C07D491/048 , C07D209/88 , C07D487/04 , H01L51/50
CPC classification number: H01L51/0072 , C07D209/86 , C07D209/88 , C07D401/10 , C07D403/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , C09K11/06 , C09K2211/1007 , C09K2211/1029 , C09K2211/1044 , C09K2211/1059 , C09K2211/1088 , C09K2211/1092 , H01L51/0067 , H01L51/0071 , H01L51/5016 , H01L51/5064 , H01L51/508 , H01L51/5092 , H01L51/5096
Abstract: A condensed cyclic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.
-
公开(公告)号:US20170362176A1
公开(公告)日:2017-12-21
申请号:US15521194
申请日:2015-10-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Saleem Ahmad , Douglas G. Batt , Qingjie Liu , John E. Macor , Joseph A. Tino , Scott Hunter Watterson
IPC: C07D209/88 , C07D487/04 , C07D471/10 , C07D403/12 , C07D401/04 , C07D403/06 , C07D403/04 , C07D401/06 , C07D495/04 , C07D471/04
CPC classification number: C07D209/88 , A61K31/4523 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D403/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D495/04
Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
公开(公告)号:US20170342031A1
公开(公告)日:2017-11-30
申请号:US15535650
申请日:2015-12-18
Applicant: Wako Pure Chemical Industries, Ltd.
Inventor: Katsufumi Suzuki , Yoshihisa Tsurumi , Kei Kawano , Shigeaki Imazeki , Tetsuji Murase
IPC: C07D209/88 , C09B69/10 , C09B11/24 , C07D491/16 , C08F20/30 , C07D493/10 , G02B5/20 , C09B69/06
CPC classification number: C07D209/88 , C07D491/16 , C07D493/10 , C08F20/30 , C09B11/24 , C09B69/06 , C09B69/103 , G02B5/20
Abstract: A quencher is disclosed having a compound represented by the following general formula (1): wherein R5 each independently represent a halogen atom, an alkyl group, an alkoxy group, an alkylthio group, an amino group having a substituent or not having a substituent, a hydroxy group, an aryl group, an aryloxy group, or an arylalkyl group; R6 represents a group having a polymerizable unsaturated group, a hydroxy group, or the like; Y1 represents an oxygen atom, or the like; An− represents an anion; Ar1 represents a specific ring structure; * and ** represent binding positions; Ar2 represents a benzene ring, a naphthalene ring, or an anthracene ring; n1 represents a specific integer; and the following structure (1-10) in the general formula (1) is an asymmetric structure; (wherein R5, Y1, Ar1, Ar2, n1, * and ** are the same as described above.).
-
公开(公告)号:US20170338416A1
公开(公告)日:2017-11-23
申请号:US15509892
申请日:2015-01-14
Inventor: JongWook PARK , JaeHyun LEE
IPC: H01L51/00 , C07D209/56 , C07D209/86 , C07D209/88 , C07D251/24 , C07D307/77 , C07D333/50 , C07D403/14 , C07D405/04 , C07D409/04 , C09K11/06 , C07C211/61 , C07C13/72 , H01L51/50 , C07C2603/97 , H01L51/52
CPC classification number: H01L51/0056 , C07C13/72 , C07C211/54 , C07C211/61 , C07C2603/18 , C07C2603/24 , C07C2603/26 , C07C2603/48 , C07C2603/50 , C07C2603/90 , C07C2603/94 , C07D209/56 , C07D209/82 , C07D209/86 , C07D209/88 , C07D251/24 , C07D307/77 , C07D307/91 , C07D333/50 , C07D403/14 , C07D405/04 , C07D409/04 , C09K11/06 , C09K2211/1011 , C09K2211/1014 , C09K2211/1018 , C09K2211/1022 , H01L51/0054 , H01L51/0058 , H01L51/006 , H01L51/0067 , H01L51/0072 , H01L51/0073 , H01L51/0074 , H01L51/5012 , H05B33/14
Abstract: The present invention relates to: an organic compound represented by a combination of Chemical Formulas 1 and 2; an organic optoelectronic device comprising the organic compound; and a display device.
-
公开(公告)号:US09812648B2
公开(公告)日:2017-11-07
申请号:US14378529
申请日:2013-01-21
Applicant: Merck Patent GmbH
Inventor: Elvira Montenegro , Amir H. Parham , Philipp Stoessel , Teresa Mujica-Fernaud , Frank Voges , Arne Buesing
IPC: C07D279/22 , C07D333/76 , C07D209/88 , C07D307/91 , C07D209/86 , C07D265/38 , C07C211/61 , C07C211/58 , H01L51/00 , C09K11/06 , C07C211/54 , H01L51/50
CPC classification number: H01L51/0058 , C07C211/54 , C07C211/58 , C07C211/61 , C07D209/86 , C07D209/88 , C07D265/38 , C07D279/22 , C07D307/91 , C07D333/76 , C09K11/06 , C09K2211/1007 , C09K2211/1011 , C09K2211/1014 , C09K2211/1029 , C09K2211/1088 , C09K2211/1092 , H01L51/006 , H01L51/0061 , H01L51/0067 , H01L51/0072 , H01L51/0073 , H01L51/5012 , H01L51/5016 , H01L51/5056 , H01L51/5096 , Y02E10/549
Abstract: Spirobifluroene compounds of the formula (1) which are suitable for use in electronic devices, and in particular organic electroluminescent devices, and to electronic devices that include the spirobifluorene compounds.
-
公开(公告)号:US20170226142A1
公开(公告)日:2017-08-10
申请号:US15494926
申请日:2017-04-24
Applicant: Achillion Pharmaceuticals, Inc.
Inventor: Jason Allan Wiles , Milind Deshpande
IPC: C07F9/6561 , C07D209/40 , C07D209/12 , C07F9/6558 , C07D403/14 , C07D471/04 , C07D401/14 , C07D413/06 , C07D403/06 , C07D209/44 , C07D209/88 , C07D491/113 , C07D209/30 , C07D417/06 , C07D417/14 , C07F5/02 , C07D413/14 , C07F7/08 , C07D487/04 , C07D471/08 , C07D209/42
CPC classification number: C07F9/5728 , A61K9/0014 , A61K9/0019 , A61K9/0048 , A61K9/0053 , A61K31/404 , A61K31/4045 , A61K31/407 , A61K31/4162 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/675 , A61K31/683 , C07B59/002 , C07B2200/05 , C07D209/12 , C07D209/14 , C07D209/30 , C07D209/40 , C07D209/42 , C07D209/44 , C07D209/88 , C07D401/14 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/14 , C07D491/113 , C07D495/04 , C07D513/04 , C07F5/025 , C07F5/027 , C07F7/0812 , C07F9/65583 , C07F9/6561 , C07F9/65616
Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
-
-
-
-
-
-
-
-
-